Nicotine Pouches Won't Make You Smarter. But They Might Addict You.

Nicotine Pouches Won't Make You Smarter. But They Might Addict You.

Dr. Jeff Kindred, DO

There's real science behind what nicotine does to the brain. And then there's what the wellness industry is doing with that science. Those two things have almost nothing to do with each other.

If you've spent any time on the internet lately — or near any man between 25 and 45 who's "dialing things in" — you've heard the pitch. Zyn is a clean way to sharpen focus. A cognitive edge without the smoke. Tech companies are stocking vending machines with them. Biohackers are putting them in their morning stacks. Dave Asprey, who has 1.3 million followers and a confident opinion about everything, has claimed nicotine can increase cognitive function and possibly reverse Alzheimer's disease.

Some of what's being said is real. Some of it is a selective reading of science that happens to be very convenient for the people selling the product. Here's how to tell the difference.

The neuroscience is legitimate — with a catch

Nicotine does have measurable cognitive effects. A meta-analysis of more than 41 double-blind, placebo-controlled studies found improvements in attention, working memory, fine motor speed, and reaction time. The mechanism is well-understood: nicotine binds receptors in the prefrontal cortex and basal ganglia, triggering dopamine and norepinephrine release. There's also genuine research interest in nicotine for Alzheimer's, Parkinson's, and ADHD. I'm not going to pretend the signal isn't there.

But here's what that meta-analysis actually showed if you read past the abstract: most of those trials were done in smokers, or in people with neurological disease. When you study a smoker, you're largely measuring relief of withdrawal — not true enhancement in a healthy brain. That's a completely different thing. When trials are restricted to nicotine-naïve adults, the effect sizes shrink considerably. A patch trial in early Alzheimer's disease is not the same intervention as you popping a Zyn before a meeting. Presenting them as equivalent is the oldest move in supplement marketing.

What's actually in the pouch

Nicotine, yes. Also plant-based cellulose filler, flavoring agents, sweeteners like maltitol or xylitol, propylene glycol, and pH adjusters — usually sodium carbonate or sodium bicarbonate. That last category matters more than people realize. Alkaline pH dramatically accelerates how fast nicotine crosses mucous membranes into your bloodstream. It's not a filler. It's engineered to make the hit faster and stronger.

This is where I find the whole thing genuinely strange. There's a real overlap between the crowd that's skeptical of vaccines — scrutinizing every ingredient, demanding to know exactly what's being put in their body — and the crowd enthusiastically using a product manufactured by Philip Morris International, with a list of additives designed to optimize nicotine delivery, because an influencer said it helped their focus. The FDA authorized Zyn for sale in January 2025, which sounds reassuring until you read what that actually means: it's less harmful than cigarettes. That's the bar. Not safe. Less harmful than one of the most dangerous consumer products ever sold.

The cardiovascular math

Every time you use a pouch, your heart rate climbs 10–20 beats per minute, your blood pressure rises 5–10 mmHg, and your peripheral vasculature constricts. These effects are temporary — an hour or two. Comparable to coffee, in isolation.

The problem is isolation. Coffee doesn't create physical dependence that has you reaching for it eight times a day regardless of whether you want to. Nicotine does.

Repeated sympathetic stimulation is not a minor footnote for someone with hypertension, an arrhythmia, or any coronary artery disease. The European Society of Cardiology has been clear: nicotine in every form — cigarettes, vapes, heated tobacco, pouches — is toxic to the cardiovascular system. And there are simply no long-term data yet on what daily nicotine pouch use does to atherosclerosis progression in healthy non-smokers. The trials don't exist. The product is too new. Anyone telling you it's safe long-term is telling you something they cannot actually know.

This is worth pairing with what I wrote about how vascular damage accumulates silently, long before anything shows up on a standard cholesterol panel. The damage that shows up at 55 was usually being laid down at 35. Anything that chronically stresses the cardiovascular system matters, even when you feel fine.

The addiction part nobody's talking about

Nicotine is among the most addictive substances we've studied. The mechanism — dopamine release in the nucleus accumbens, receptor upregulation, withdrawal dysphoria when levels drop — is identical whether the delivery vehicle is a cigarette or a pouch with minimalist Scandinavian design.

The receptor adaptation happens fast. What starts as a pouch when you need to focus turns into a pouch in the morning, a pouch after lunch, a pouch when you're stressed, a pouch when you're bored. Not because you're weak. Because that's what nicotine does to receptors. It happens faster in people who've never used nicotine before, because there's no existing tolerance, and the brain responds to the first exposures more dramatically.

The wellness industry has a strong incentive to tell you the upside story and a weak incentive to tell you about the patient who came to me having quietly become dependent on something they started "for productivity." That person exists. More than one of them.

The bottom line

If you're a non-smoker using Zyn to focus, you're not biohacking. You're trading addiction risk and unquantified cardiovascular risk for a modest, transient cognitive effect that the data doesn't reliably demonstrate in healthy adults. When a wellness brand sells you a product without long-term safety data, that's a problem. When a tobacco company does it with cleaner packaging and an influencer distribution network, it's the same problem with a much bigger budget behind it.

The biohacking space does this pattern regularly — take a real mechanism from a legitimate body of research, strip out the context, and sell it back to you as optimization. I wrote about the same dynamic when it comes to what gets cherry-picked from the metabolic research on fatigue and performance. The nicotine story is the same structure.

Read the full study, not just what the influencer quoted from it.

If you want help separating the signal from the noise on performance, longevity, and what's actually worth doing for your health — that's exactly what I do. Set up a consultation.

Related reading:

References:

  1. Heishman SJ, et al. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210(4):453–469. PMC3151730
  2. Moran-Santa Maria MM, et al. Cognitive performance effects of nicotine and industry affiliation: a systematic review. Nicotine Tob Res. 2020;22(8):1246–1253. PMC7271274
  3. European Society of Cardiology. Vapes, pouches, heated tobacco, shisha, cigarettes: nicotine in all forms is toxic to the heart and blood vessels. 2024. escardio.org
  4. Frontiers in Public Health. Nicotine pouches and youth: emerging patterns and potential cardiovascular risks. 2025. PMC12675456
  5. STAT News. Biohackers and wellness influencers are pushing nicotine as part of their "stacks." February 2026. statnews.com
back to Blog
Shop nowBook Now